Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer

Acta Obstetricia et Gynecologica Scandinavica

Volumn 87, Issue 10, 2008, Pages 1060-1070

  Tokunaga, Hideki ^a   Takebayashi, Yuji ^b   Utsunomiya, Hiroki ^a   Akahira, Jun Ichi ^a   Higashimoto, Masashi ^b   Mashiko, Miyuki ^b   Ito, Kiyoshi ^a   Niikura, Hitoshi ^a   Takenoshita, Sei Ichi ^b   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Circadian gene; Ovarian cancer

Indexed keywords

PER1 PROTEIN; PER2 PROTEIN; PROTEIN BMAL1; TRANSCRIPTION FACTOR CLOCK;

ADULT; AGED; ARTICLE; BMAL1 GENE; CANCER PATIENT; CANCER TISSUE; CIRCADIAN RHYTHM; CKIEPSILON GENE; CLOCK GENE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CRY1 GENE; CRY2 GENE; FEMALE; GENE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MUCINOUS CARCINOMA; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PATHOLOGY; PER1 GENE; PER2 GENE; PER3 GENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADENOCARCINOMA; ADULT; AGED; CELL CYCLE PROTEINS; CIRCADIAN RHYTHM; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION; MIDDLE AGED; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 53849124685     PISSN: 00016349     EISSN: 16000412     Source Type: Journal    
DOI: 10.1080/00016340802348286     Document Type: Article

References (45)

1. Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398-403.
2. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138-50.
3. Del Campo JM, Felip E, Rubio D, Vidal R, Bermejo B, Colomer R, et al. Long-term survival in advanced ovarian cancer after cytoreduction and chemotherapy treatment. Gynecol Oncol. 1994;53:27-32.
4. Akahira J, Inoue T, Suzuki T, Ito K, Konno R, Sato S, et al. Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies. Br J Cancer. 2000;83:1488-94.
5. Kaufmann M, Von Minckwitz G, Kuhn W, Schmid H, Costa S, Goerttler K, et al. Combination of new biologic parameters as a prognostic index in epithelial ovarian carcinoma. Int J Gynecol Cancer. 1995;5:49-55.
6. Cooper BC, Sood AK, Davis CS, Ritchie JM, Sorosky JI, Anderson B, et al. Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer. Obstet Gynecol. 2002;100:59-64.
7. Pittendrigh CS. Temporal organization: reflections of a Darwinian clock-watcher. Annu Rev Physiol. 1993;55:16-54.
8. You S, Wood PA, Xiong Y, Kobayashi M, Du-Quiton J, Hrushesky WJ. Daily coordination of cancer growth and circadian clock gene expression. Breast Cancer Res Treat. 2005;91:47-60.
9. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006;15:271-7.
10. Vitaterna MH, King DP, Chang AM, Kornhauser JM, Lowrey PL, McDonald JD, et al. Mutagenesis and mapping of a mouse gene, clock, essential for circadian behavior. Science. 1994;264:719-25.
11. King DP, Zhao Y, Sangoram AM, Wilsbacher LD, Tanaka M, Antoch MP, et al. Positional cloning of the mouse circadian clock gene. Cell. 1997;89:641-53.
12. Tei H, Okamura H, Shigeyoshi Y, Fukuhara C, Ozawa R, Hirose M, et al. Circadian oscillation of a mammalian homologue of the Drosophila period gene. Nature. 1997;389:512-6.
13. Sun ZS, Albrecht U, Zhuchenko O, Bailey J, Eichele G, Lee CC. RIGUI, a putative mammalian ortholog of the Drosophila period gene. Cell. 1997;90:1003-11.
14. Gekakis N, Staknis D, Nguyen HB, Davis FC, Wilsbacher LD, King DP, et al. Role of the CLOCK protein in the mammalian circadian mechanism. Science. 1998;280:1564-9.
15. Sangoram AM, Saez L, Antoch MP, Gekakis N, Staknis D, Whiteley A, et al. Mammalian circadian autoregulatory loop: a timeless ortholog and mPer1 interact and negatively regulate CLOCK-BMAL1-induced transcription. Neuron. 1998;21:1101-13.
16. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93:1557-62.
17. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001;93:1563-8.
18. Sahar S, Sassone-Corsi P. Circadian clock and breast cancer: a molecular link. Cell Cycle. 2007;6:1329-31.
19. Cai W, Rambaud J, Teboul M, Masse I, Benoit G, Gustafsson JA, et al. Expression levels of estrogen receptor beta are modelated by components of the molecular clock. Mol Cell Biol. 2008;28:784-93.
20. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. 2007;26:7916-20.
21. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology. 2005;16:254-8.
22. Srinivasan V, Maestroni G, Cardinali D, Esquifino A, Perumal SP, Miller S. Melatonin, immune function and aging. Immun Ageing. 2005;2:17.
23. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000;92:994-1000.
24. Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res. 2000;6:3038-45.
25. Mormont MC, Levi F. Circadian-system alterations during cancer processes: a review. Int J Cancer. 1997;70:241-7.
26. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350-61.
27. Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002;417:78-83.
28. Shih HC, Choo KB, Chang TJ, Yang MY, Shih MC, Yeh KT, et al. Disturbance of circadian gene expression in endometrial cancer: detection by real-time quantitative RT-PCR. Oncol Rep. 2005;14:1533-8.
29. Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005;26:1241-6.
30. Hrushesky WJ. Circadian timing of cancer chemotherapy. Science. 1985;228:73-5.
31. Hrushesky WJ, Bjarnason GA. Circadian cancer therapy. J Clin Oncol. 1993;11:1403-17.
32. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst. 1994;86:1608-17.
33. Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997;350:681-6.
34. Klevecz RR, Shymko RM, Blumenfeld D, Braly PS. Circadian gating of S phase in human ovarian cancer. Cancer Res. 1987;47:6267-71.
35. Klevecz RR, Braly PS. Circadian and ultradian rhythms of proliferation in human ovarian cancer. Chronobiol Int. 1987;4:513-23.
36. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, Silverberg SG. Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features - problems involved in the architectural grading system. Gynecol Oncol. 1998;70:2-12.
37. Wang YQ, Hua H, Zhu B, Yin HH, Liu YY, Yang CL, et al. The influence of circadian gene mPeriod2 on Lewis cancer cell]. Space Med Med Eng (Beijing). 2005;18:222-3.
38. Filipski E, King VM, Li X, Granda TG, Mormont MC, Liu X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst. 2002;94:690-7.
39. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111:41-50.
40. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005;25:3109-16.
41. Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H. Control mechanism of the circadian clock for timing of cell division in vivo. Science. 2003;302:255-9.
42. Gauger MA, Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 2005;65:6828-34.
43. Ko CH, Takahashi JS. Molecular components of the mammalian circadian clock. Hum Mol Genet. 2006;15(2):R271-7.
44. Hess V, A'Hern R, Nasiri N, King DM, Blake PR, Barton DP, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-4.
45. Gorbacheva VY, Kondratov RV, Zhang R, Cherukuri S, Gudkov AV, Takahashi JS, et al. Circadian sensitivity to the chemotherapeutic agent cyclophosphamide depends on the functional status of the CLOCK/BMAL1 transactivation complex. Proc Natl Acad Sci U S A. 2005;102:3407-12.